Comparative analysis of European guideline-based clinicopathological risk groups and the International Federation of Gynecology and Obstetrics staging system for endometrial cancer

被引:0
|
作者
Loukovaara, Mikko J. [1 ,2 ,3 ]
Pasanen, Annukka M. [4 ,5 ]
Lassus, Heini J. [1 ,2 ]
Luomaranta, Anna L. [1 ,2 ]
Hellberg, Piret [1 ,2 ]
Vartiainen, Johanna [1 ,2 ]
Tapper, Johanna E. [1 ,2 ]
Butzow, Ralf C. [1 ,2 ,4 ,5 ]
机构
[1] Helsinki Univ Hosp, Dept Obstet & Gynecol, POB 180 HUS, Helsinki 00029, Finland
[2] Univ Helsinki, POB 180 HUS, Helsinki 00029, Finland
[3] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland
[4] Helsinki Univ Hosp, Dept Pathol, Helsinki, Finland
[5] Univ Helsinki, Fac Med, Res Program Appl Tumor Genom, Helsinki, Finland
关键词
Endometrial cancer; Mismatch repair; Polymerase-is an element of; p53; Stage; Survival; CELL-ADHESION MOLECULE; CLASSIFICATION; CARCINOMA;
D O I
10.1016/j.ejogrb.2025.02.049
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To investigate the correlation between endometrial cancer risk groups, as defined by the 2021 European guidelines, and the 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system. Further, we aimed to evaluate the additional prognostic capability of the staging system within individual risk groups. Study design: This retrospective cohort study included patients who underwent primary treatment for endometrial cancer at a single tertiary center. Each case was classified into a molecular-integrated risk group according to the 2021 joint guidelines from the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP). Staging was performed using the FIGO 2023 criteria with molecular classification. Results: Data from 1044 patients were analyzed. Median follow-up was 70 months. Stage IA2, stage IB, and stage IVB were the most prevalent stages among the ESGO-ESTRO-ESP low-risk, intermediate risk, and advanced- metastatic groups, accounting for 80 %, 75 %, and 54 % of the cases, respectively. The stage distribution was more heterogeneous in the high-intermediate risk and high-risk groups, with stage IIA comprising 36 % and stage IICmp53abn comprising 35 % of cases in these groups. The FIGO staging system further stratified survival outcomes especially in the high-intermediate and high-risk groups. Stage IIC included a substantial number of cases from the intermediate risk (n = 23), high-intermediate risk (n = 48), and high-risk (n = 27) groups. Risk groups were associated with survival within this stage. Conclusions: ESGO-ESTRO-ESP high-intermediate risk and high-risk endometrial cancers exhibited the greatest variability in terms of stage distribution and survival outcomes. Stage IIC, the most heterogeneous stage concerning risk groups, showed an association between risk groups and survival.
引用
收藏
页码:85 / 89
页数:5
相关论文
共 50 条
  • [21] Comparing survival outcomes for cervical cancer based on the 2014 and 2018 International Federation of Gynecology and Obstetrics staging systems
    Wonkyo Shin
    Tae Young Ham
    Young Ran Park
    Myong Cheol Lim
    Young-Joo Won
    Scientific Reports, 11
  • [22] Comparing survival outcomes for cervical cancer based on the 2014 and 2018 International Federation of Gynecology and Obstetrics staging systems
    Shin, Wonkyo
    Ham, Tae Young
    Park, Young Ran
    Lim, Myong Cheol
    Won, Young-Joo
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [23] Assessment of the revised International Federation of Gynecology and Obstetrics staging for early invasive squamous cervical cancer
    Takeshima, N
    Yanoh, K
    Tabata, T
    Nagai, K
    Hirai, Y
    Hasumi, K
    GYNECOLOGIC ONCOLOGY, 1999, 74 (02) : 165 - 169
  • [24] Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer (vol 201, 113913, 2024)
    Gravbrot, Nicholas
    Weil, Christopher R.
    Decesaris, Cristina M.
    Gaffney, David K.
    Suneja, Gita
    Burt, Lindsay M.
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [25] Stage III Uterine Carcinosarcoma 2009 International Federation of Gynecology and Obstetrics Staging System and Prognostic Determinants
    Garg, Gunjal
    Kruger, Michael
    Christensen, Carl
    Deppe, Gunter
    Toy, Eugene P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (09) : 1606 - 1612
  • [26] Quality of Life of Patients With Endometrial Cancer Undergoing Laparoscopic International Federation of Gynecology and Obstetrics Staging Compared With Laparotomy: A Gynecologic Oncology Group Study
    Kornblith, Alice B.
    Huang, Helen Q.
    Walker, Joan L.
    Spirtos, Nick M.
    Rotmensch, Jacob
    Cella, David
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) : 5337 - 5342
  • [27] Is the extent of lymphadenectomy a prognostic factor in International Federation of Gynecology and Obstetrics stage II endometrioid endometrial cancer?
    Cuylan, Zeliha Firat
    Akilli, Huseyin
    Gungorduk, Kemal
    Demirkiran, Fuat
    Oz, Murat
    Salman, Mehmet Coskun
    Sozen, Hamdullah
    Celik, Husnu
    Gokcu, Mehmet
    Bese, Tugan
    Meydanli, Mehmet Mutlu
    Ozgul, Nejat
    Topuz, Samet
    Kuscu, Esra
    Kuru, Oguzhan
    Gokmen, Sibel
    Gultekin, Murat
    Ayhan, Ali
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2021, 47 (03) : 1134 - 1144
  • [28] Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world
    Gupta, Nidhi
    Pandey, Awadhesh
    Dimri, Kislay
    Sehgal, Alka
    Bhagat, Ranjeev
    Suraj
    Gill, Gurbir
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (03) : 701 - 707
  • [29] External Validation of the New 2023 International Federation of Gynecology and Obstetrics Staging System in Endometrial Cancer Patients: 12-Year Experience from an European Society of Gynecological Oncology-Accredited Center
    Tsolakidis, Dimitrios
    Zouzoulas, Dimitrios
    Sofianou, Iliana
    Karalis, Tilemaxos
    Chatzistamatiou, Kimon
    Theodoulidis, Vasilis
    Topalidou, Maria
    Timotheadou, Eleni
    Grimbizis, Grigoris
    MEDICINA-LITHUANIA, 2024, 60 (09):
  • [30] Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain
    Salvo, Gloria
    Odetto, Diego
    Pareja, Rene
    Frumovitz, Michael
    Ramirez, Pedro T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (06) : 873 - 878